Palaniappan Jyoti 4
4 · Adaptive Biotechnologies Corp · Filed Jun 21, 2021
Insider Transaction Report
Form 4
Palaniappan Jyoti
SVP, Diagnostics, immunoSEQ Dx
Transactions
- Sale
Common Stock
2021-06-17$40.00/sh−651$26,040→ 9,158 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-06-18−1,301→ 105,344 totalExercise: $22.55Exp: 2030-03-19→ Common Stock (1,301 underlying) - Exercise/Conversion
Common Stock
2021-06-17$22.55/sh+651$14,680→ 9,809 total - Sale
Common Stock
2021-06-18$39.80/sh−1,301$51,780→ 9,158 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-06-17−651→ 106,345 totalExercise: $22.55Exp: 2030-03-19→ Common Stock (651 underlying) - Exercise/Conversion
Common Stock
2021-06-18$22.55/sh+1,301$29,338→ 10,459 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020.
- [F2]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.59 to 40.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The options vested with respect to 1/4 of such shares on March 18, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.